Table 1. An overview on approved compounds for the indication “glioblastoma”.
Name | Target structure | Year of Approval | Year of designation |
---|---|---|---|
5-aminolevulinic acid | intraoperative optical imaging agent | 2017 | 2013 |
Bevacizumab | Inhibition of angiogenesis (antibody against VEGF) | 2009 | 2006 |
Polifeprosan 20 with carmustine | Implant to deliver the approved drug carmustine | 2003 | 1989 |
Lomustine | Alkylating compound | 1976 | unknown |
Temozolomide | Alkylating compound | 2006 | 1998 |